Close
ACHEMA MIDDLE EAST 2026

Biotech M&A Is Set For Rebound With Billion-Dollar Deals

2022 was an unremarkable year for biotech mergers and acquisitions (M&A) as the industry experienced a decline in both the number and value of...

New Guidelines: Medicare To Directly Negotiate Drug Prices

The Biden administration has issued new guidelines for its program that enables Medicare to directly negotiate drug prices with manufacturers. The updated guidelines provide...

Environmental Consciousness Rising In Global Healthcare

The global healthcare sector is increasingly embracing environmentally conscious practices, particularly in the pharmaceutical industry, which is prioritizing initiatives aligned with environmental, social, and...

Swiss Pharma Sector In EU Negotiations- Stakes Are Sky High

In a recent development, Switzerland may very well lose out as a manufacturing location if its differences with the European Union are not sorted...

$85bn M&A Splurge Helps In Big Pharma Dealmaking Recovery

It is well to be noted that pharma and biotech companies splurged a whopping $85 billion in the first five months of 2023, which...

Advancing RNA Therapeutics With UK Drug Delivery Centre

The Centre for Process Innovation (CPI) plans to establish a new Intracellular Drug Delivery Centre in the UK to develop innovative lipid nanoparticle (LNP)...

WHO And Korea Sign MoU For Biomanufacturing Training Hub

The World Health Organisation as well as the Republic of South Korea have gone ahead and inked a MoU so as to establish a...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...